20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, we have successful pre-clinical studies in glaucoma, dry eye and uveitis.
20/20 OptimEyes Technologies is seeking partners to further develop ophthalmic assets or those with novel or repurposed APIs for co-development opportunities in humans and companion animals. The company is also looking for partners with assets targeting other mucosal areas (nasal, optic, buccal, vaginal or GI).
20|20 OptimEyes Technologies is a biotechnology spin-out company from McMaster University located in Hamilton, Ontario, Canada. We are developing a transformative drug for mucosal delivery while initially focusing on eye drops. Using a patented technology formulation, initially targeted for glaucoma and dry eye diseases, we are able to change the dosing paradigm from twice daily to once or twice weekly. This will revolutionize treatment for patients, improving their comfort, compliance and clinical outcomes.
OptimEyes’ MNP technology is a next generation drug delivery platform that maximizes the efficacy of new and existing APIs to improve patients lives
20|20 OptimEyes Technologies are committed to improving treatments for patients suffering from vision loss and other ocular conditions. Led by a talented team and experienced key advisors, we are de-risking our patented mucoadhesive micelle nanoparticles technology, initially for the treatment of Glaucoma and dry eye disease.
Our business strategy is dual pronged. We are working on internal product development utilizing existing therapeutics, such as cyclosporine A for dry eye disease and latanoprost for glaucoma. We are also interested in external collaborations, using strategic partnerships to examine novel therapeutics with our formulation. These are therapeutics that could benefit from lower doses, controlled release, higher solubility or a reduced dosing regimen.
We also have the capacity to conduct animal testing, allowing us to use your drugs to complete feasibility studies and if successful, proceed immediately into low cost animal studies using our state of the art Phoenix Ganzfeld ERG and Heidelberg Spectralis OCT.
